ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 59 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,250,348 | +1.9% | 3,078,633 | -8.5% | 6.42% | -5.2% |
| Q2 2023 | $34,578,713 | +19.7% | 3,363,688 | -10.1% | 6.77% | +19.4% |
| Q1 2023 | $28,878,675 | +8.0% | 3,740,761 | +2.8% | 5.67% | +8.2% |
| Q4 2022 | $26,737,227 | +7.7% | 3,637,718 | +5.5% | 5.24% | -12.3% |
| Q3 2022 | $24,829,000 | +441.5% | 3,448,521 | +540.0% | 5.98% | +443.5% |
| Q2 2022 | $4,585,000 | – | 538,819 | – | 1.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |